Are you saying that they should have consulted the guy whose drug only extended survival by a couple of months about an immune therapy trial that extended survival multiples of that? Who's drug was potentially shown to interfere with the patient's immune systems such that survival was just as long without it in patients with rGBM who started the therapy later?